SCHEMBL5475766

SCHEMBL5475766

Cc1cc(C)c(/C=C2\C(=O)Nc3cccc(Cl)c32)[nH]1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 11/20 0.64
KDR P35968 5/20 0.64
FLT3 P36888 4/20 0.64
ALK Q9UM73 4/20 0.64
PDGFRB P09619 3/20 0.64
CSF1R P07333 2/20 0.64
FGFR1 P11362 2/20 0.64
SRC P12931 2/20 0.64
FLT1 P17948 2/20 0.64
FGFR3 P22607 2/20 0.64
MAPK1 P28482 2/20 0.64
FLT4 P35916 2/20 0.64
PDPK1 O15530 2/20 0.64
ABL1 P00519 2/20 0.64
MEN1 O00255 1/20 0.64
NPC1 O15118 1/20 0.64
GMNN O75496 1/20 0.64
USP2 O75604 1/20 0.64
LMNA P02545 1/20 0.64
MAPT P10636 1/20 0.64

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5475770 1.00 RET (0.64) RETKDRFLT3ALKPDGFRB
SCHEMBL13432277 0.88 RET (0.69) RETKDRFLT3ALKPDGFRB
SCHEMBL5475402 0.85 RET (0.64) RETKDRFLT3ALKPDGFRB
SCHEMBL5475395 0.85 RET (0.64) RETKDRFLT3ALKPDGFRB
SCHEMBL6328758 0.83 RET (0.63) RETKDRFLT3ALKPDGFRB
SCHEMBL6767365 0.83 RET (0.63) RETKDRFLT3ALKPDGFRB
SCHEMBL6321965 0.83 RET (0.62) RETKDRFLT3ALKPDGFRB
SCHEMBL6321958 0.83 RET (0.62) RETKDRFLT3ALKPDGFRB
SCHEMBL5470645 0.81 RET (0.60) RETKDRFLT3ALKPDGFRB
SCHEMBL5470642 0.81 RET (0.60) RETKDRFLT3ALKPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US claimed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO claimed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
US-20070167488-A1 Novel therapeutic use LEO PHARMA A/S (DK) 2007-07-19 US disclosed
EP-1696906-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES Leo Pharma A/S (DK) 2006-09-06 EP disclosed
WO-2005058309-A1 NOVEL THERAPEUTIC USE OF INDOLINONE DERIVATIVES LEO PHARMA A/S (DK) 2005-06-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070167488-A1 Novel therapeutic use MAG, PMP22, MYT1 RET 3720/4885KDR 4334/4885FLT3 4311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.